GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.50
Ask: 41.50
Change: -1.40 (-3.30%)
Spread: 1.00 (2.469%)
Open: 41.50
High: 41.50
Low: 40.50
Prev. Close: 42.40
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor Briefing

29 Sep 2014 07:00

RNS Number : 7880S
Avacta Group PLC
29 September 2014
 



29 September 2014

Avacta Group plc

("Avacta" or the "Group")

 

Investor Results Briefing

 

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces it will be hosting an investor results presentation on Thursday 16 October 2014 where Alastair Smith, CEO, Craig Slater, COO and Tim Sykes, CFO will present the Company's results for its financial year ended 31 July 2014.

 

The investor event, open to all investors, will be held from 16:30 at the Black Bar, Rocket, 6 Adams Court, EC2N 1DX followed by drinks and canapés.

 

For more information or to register to attend, contact Walbrook PR (contact details are below).

 

 

 

 

Enquiries:

 

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tim Sykes, Chief Financial Officer

Tel: +44 (0) 844 414 0452

www.avacta.com

Numis Securities Limited

Michael Meade / Freddie Barnfield - Nominated Adviser

James Black - Corporate Broking

Tel: +44 (0) 207 260 1000

www.numiscorp.com

Media Enquiries

Walbrook PR Ltd

Anna Dunphy / Mike Wort

Tel: +44 (0) 207 933 8780

avacta@walbrookpr.com

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASEAFMMFLSESU
Date   Source Headline
13th Apr 20227:00 amRNSAffyXell milestone and increased equity stake
12th Apr 20227:00 amRNSPoster presented at the AACR available to download
11th Apr 20224:41 pmRNSSecond Price Monitoring Extn
11th Apr 20224:35 pmRNSPrice Monitoring Extension
11th Apr 20222:05 pmRNSSecond Price Monitoring Extn
11th Apr 20222:00 pmRNSPrice Monitoring Extension
8th Apr 20221:57 pmRNSIssue of Equity and Total Voting Rights
8th Apr 20227:00 amRNSAffyXell partners with Biocytogen and KNTSC
7th Apr 20224:31 pmRNSIssue of Equity and Total Voting Rights
6th Apr 20227:00 amRNSPreliminary Results
30th Mar 20224:41 pmRNSSecond Price Monitoring Extn
30th Mar 20224:35 pmRNSPrice Monitoring Extension
30th Mar 20227:00 amRNSNotice of Results and Investor Presentation
29th Mar 20227:00 amRNSAVA6000 data poster presentation at AACR
21st Mar 20227:00 amRNSDirectorate Change
16th Mar 20227:00 amRNSVimian acquires Avacta’s Animal Health Division
14th Feb 20224:41 pmRNSSecond Price Monitoring Extn
14th Feb 20224:36 pmRNSPrice Monitoring Extension
7th Feb 20224:36 pmRNSPrice Monitoring Extension
3rd Feb 20225:26 pmRNSIssue of Equity and Total Voting Rights
3rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20224:35 pmRNSPrice Monitoring Extension
3rd Feb 20227:00 amRNSDose escalation in the phase I trial of AVA6000
31st Jan 20224:41 pmRNSSecond Price Monitoring Extn
31st Jan 20224:36 pmRNSPrice Monitoring Extension
18th Jan 20227:00 amRNSSecond pre|CISION Pro-drug Candidate Selected
12th Jan 20222:05 pmRNSSecond Price Monitoring Extn
12th Jan 20222:00 pmRNSPrice Monitoring Extension
10th Jan 20227:00 amRNSUpdate on AffiDX and detection of Omicron variant
4th Jan 202211:06 amRNSSecond Price Monitoring Extn
4th Jan 202211:01 amRNSPrice Monitoring Extension
22nd Dec 20214:26 pmRNSIssue of Equity and Total Voting Rights
22nd Dec 202111:05 amRNSSecond Price Monitoring Extn
22nd Dec 202111:00 amRNSPrice Monitoring Extension
22nd Dec 20217:00 amRNSAffiDX Receives CE Mark for Consumer Self-Testing
16th Dec 20217:00 amRNSIssue of Equity and Total Voting Rights
15th Dec 20217:00 amRNSAffiDx® lateral flow test detects Omicron variant
15th Dec 20217:00 amRNSChange of auditor
29th Nov 20217:00 amRNSFDA Approval of IND Application for AVA6000
18th Nov 20214:41 pmRNSSecond Price Monitoring Extn
18th Nov 20214:36 pmRNSPrice Monitoring Extension
2nd Nov 20217:00 amRNSUpdate on UK Availability of AffiDX Test
14th Oct 20214:36 pmRNSPrice Monitoring Extension
14th Oct 202112:36 pmRNSIssue of Equity and Total Voting Rights
30th Sep 20217:00 amRNSInterim Results for the Period Ended 30 June 2021
29th Sep 20217:00 amRNSDevelopment Milestone in LG Chem Partnership
9th Sep 20217:00 amRNSNotice of Results
2nd Sep 20217:00 amRNSAppointment of Chief Scientific Officer
25th Aug 20214:40 pmRNSSecond Price Monitoring Extn
25th Aug 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.